Ensuring the Microbiological Integrity of Pharmaceutical and Biopharmaceutical Facilities
Frank Settineri
90 Min
Product Id: 701145
This Microbiology training/webinar will provide a new approach in ensuring the Microbiological Integrity of Pharmaceutical and Biopharmaceutical Facilities.
Japanese PAL - JPAL QMS requirements in Ordinance 169 and differences to ISO 13485
Phil Smart
90 Min
Product Id: 701290
This JPAL (Japanese Pharmaceutical Affairs Law) QMS training/webinar will explore, in detail, the QMS requirements placed on the foreign manufacturer via Ministerial Ordinance 169, Ordinance 2 and Ordinance 179.
Japanese PAL - Dealing with a JPAL Quality Interface Agreement between the foreign manufacturer and MAH (Marketing Authorization Holder)
Phil Smart
90 Min
Product Id: 701277
This JPAL training will describe requirements, common mistakes & best practices while dealing with a JPAL Quality Interface Agreement between the foreign manufacturer and MAH (Marketing Authorization Holder).
Water System Compliance - What Makes Water Systems Have Microbial Quality Problems
T.C Soli
90 Min
Product Id: 701283
This Water System Compliance training will review what biofilm is and how it grows and will cover how it affects just about every kind of unit operation used in today's water systems.
Japanese PAL - Navigating the Japanese Pharmaceutical Affairs Law
Phil Smart
90 Min
Product Id: 701276
This JPAL training will emphasize on Japanese Pharmaceutical Affairs law with respect to - Classification, device approvals, clinical data, MAH (Marketing Authorization Holder),foreign manufacturer accreditation,QMS,post-market complaints & vigilance
Auditing and Compliance of Biopharmaceutical API Facilities
Frank Settineri
90 Min
Product Id: 701208
This FDA audit training will review the fundamental aspects of auditing biopharmaceutical API facilities to ensure their compliance with current regulatory guidelines.
Violation...Deviation: Whatever you call them, you need a process to manage them
Tina D Forrister
60 Min
Product Id: 701125
This presentation will discuss the rationale for a process and offer suggestions including definitions and methods for documentation and communication. One of the most common inspection findings is a failure by the Investigator "…to conduct the studies or ensure they were conducted according to the investigational plans". Often, the citation isn't just that the protocol wasn't followed but that documentation surrounding management of the issue is insufficient. Therefore, Sponsors are well served by having an effective process to identify, document, and communicate departures from the investigational plan. This presentation will discuss the rationale for a process and offer suggestions including definitions and methods for documentation and communication.
Maintenance and Calibration of Equipment
Michelle Sceppa
60 Min
Product Id: 701188
This Pharmaceutical compliance training will provide instruction on how to establish and maintain a Maintenance & Calibration program for pharmaceutical instrumentation & equipment.
Investigations of Microbial Data Deviations
Scott Sutton
90 Min
Product Id: 701239
This Biotech training will provide valuable assistance to all regulated companies that need to investigate product issues.
What are best practices for creating a Risk Management File?
Dennis Moore
60 Min
Product Id: 701233
This Quality management training will review processes for integrating a reasonable level of risk management into the quality management system.
Auditing for Microbiological Aspects of Pharmaceutical and Biopharmaceutical Manufacturing
Frank Settineri
90 Min
Product Id: 701186
This Pharmaceutical compliance training will outline actions to take to ensure the microbiological wellness of your facility and will introduce the concept of "Thinking like a Bug".
Virtual Manufacturing - how to manage third party contract manufacturers
Peter Calcott
60 Min
Product Id: 701228
This Pharmaceutical training will describe strategies and tactics with concrete examples of how you can set up quality systems that will assure compliance and successful operations and will satisfy the agencies.
Validation of Rapid Microbiological Methods
Scott Sutton
90 Min
Product Id: 701240
This biotech training will look at different methods to validate the alternate method and Validating of Rapid Microbiological Methods.
Qualification and Audit of Suppliers and Vendors - A Risk Based Approach
Michelle Sceppa
60 Min
Product Id: 701189
This Pharmaceutical compliance training will demonstrate how to implement an effective audit program for both manufacturing and the laboratory and the ability to maintain GMP/GLP/GCP compliance with all suppliers and/or vendors.
Delivering Biopharmaceutical Facilities in a Risk Based World: The Role of GEP, QbD, and E2500
Jeff Odum
60 Min
Product Id: 701207
This Biopharmaceutical training will introduce and link the concepts of GEP and QbD and also identify synergies with the new ASTM E2500 standard Biopharmaceutical Active Pharmaceutical Ingredients (APIs) must be produced according to Good Manufacturing Practices outlined in FDA and ICH guidelines in order to be marketed to the public. This webinar will review the areas that an inspector may examine when conducting an audit of a biopharmaceutical API supplier to ensure it complies with regulatory requirements.
Cleaning & Cleaning Validation; an Overview
Gamal Amer
60 Min
Product Id: 701149
In this Cleaning validation training we will discuss preparing the cleaning validation protocol. Important aspects such as how to set acceptance criteria and how to measure cleanliness will then be reviewed.
Corrective And Preventive Action: CAPA-A Risk Mitigating Quality System
Gamal Amer
60 Min
Product Id: 701146
This CAPA training will focus on defining the specific steps to be taken when implementing a CAPA system and review some of the possible pitfalls one may encounter when implementing a CAPA system. This presentation will begin by defining risk in compliance and the methods, which can be used to mitigate risk. One of the methods defined by the regulators and the industry is “Corrective Action Preventive Action” otherwise referred to CAPA. We will first define what we mean by risk. We will then explore the factors associated with risk in compliance. We will also explore risk causing events and how to address them. A review of risk severity/level will then ensue. Upon completion of risk part of the presentation we will define what a CAPA system would look like.
The presentation will focus on CAPA as it applies to risk mitigation. We will define what we mean by a CAPA system. We will further define the tools CAPA uses during implementation. Finally an overview of a CAPA system will be presented and a CAPA approach will be proposed. The approach will focus on defining the specific steps to be taken when implementing a CAPA system and review some of the possible pitfalls one may encounter when implementing a CAPA system. We will also review some of the benefits which may accrue by having a robust CAPA system in place.
Using ICH Q9 and Recent FDA Comments as the Foundation for the Planning, Development and Execution of Risk-Based Cleaning Validation Studies
John Hyde
90 Min
Product Id: 701184
This Cleaning validation training will provide valuable assistance to all regulated companies that need to develop and validate their equipment cleaning processes. This session will address risk-based approaches to cleaning validation studies using ICH Q9 and recent FDA comments and observations as a foundation. Recent FDA warning letters illustrate just how critical good cleaning practices are. Understanding and employing good cleaning practices are instrumental to improving cleaning consistency, quality and traceability. The FDA favors automated CIP systems since they reduce operator variability while enhancing consistency and reproducibility. Our research has indicated that in the last 5 years, cleaning citations were noted in 50% of warning FDA letters. Many cited contamination issues have an element of poor cleaning practices associated with them. Examples include “investigations…did not include an evaluation of the cleaning processes and procedures…to determine if equipment cleaning is effective in preventing cross contamination of the inactivated batches”, FDA Warning Letter, Jan 2008; "vaccine manufacturing plant in Pennsylvania, has been served with an FDA warning letter asking for measures to ensure batches of its flu shot ingredients do not become contaminated again.” Jul-2006..
An overview of ICH risk management techniques and how to apply them to equipment cleaning programs will be discussed. In addition, case studies from manufacturing facilities will be used to illustrate risk-based cleaning validation principles and practices.
Residual Solvent Analysis According to USP <467> - Understanding and implementing the new USP chapter
Dr. Ludwig Huber
60 Min
Product Id: 701156
This Laboratory compliance training will help to understand and implement the new USP chapter.
Implementing Human Factors in Manufacturing
Ginette M Collazo
90 Min
Product Id: 706999
This course on Implementing Human Factors in Manufacturing provides a comprehensive overview of how to integrate human factors principles into manufacturing processes to reduce errors, improve safety and quality, and enhance operational efficiency. Participants will learn about the types and causes of human errors, ergonomic design principles, human-machine interface optimization, and effective strategies for fostering a culture of safety, quality, and continuous improvement. Through interactive workshops, case studies, and practical applications, attendees will gain the tools needed to conduct human factors assessments, design effective training programs, and develop actionable plans for sustainable improvement in their organizations.







